华仁药业(300110.SZ)：参与京津冀“3+N”联盟部分西药和中成药带量联动接续采购中选

Core Insights - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Performance - The selected products are expected to generate a total sales revenue of 13.0389 million yuan in 2024, accounting for 0.96% of the company's total revenue for the year [1] - The revenue breakdown for the selected products includes: - Mixed sugar electrolyte injection: 823,200 yuan (0.06% of total revenue) - Betahistine hydrochloride sodium injection: 2,220,300 yuan (0.16% of total revenue) - Hydroxyethyl starch 130/0.4 sodium chloride injection: 9,995,400 yuan (0.74% of total revenue) [1] Group 2: Product Details - The selected products and their specifications include: - Mixed sugar electrolyte injection (500ml) priced at 15.29 yuan per bag, used for hydration and electrolyte maintenance [2] - Betahistine hydrochloride sodium injection (0.02g) priced at 5.76 yuan per bottle, primarily for Meniere's disease and related conditions [2] - Hydroxyethyl starch 130/0.4 sodium chloride injection available in multiple specifications, priced between 3.56 and 6.05 yuan per bag, used for treating and preventing blood volume deficiency [2]